

Company Report

China Merchants Securities (HK) Co., Ltd.
Hong Kong Equity Research

SJM (880 HK)

4Q15 huge miss; dividends cut; maintain SELL

- 4Q15 adj. EBITDA of HK\$716mn (-54% YoY, -19% QoQ) missed our/market est. by 39%/38% on operating deleverage. 57% DPS payout ratio (HK\$0.25) also worse than that of 70% in FY14
- We cut FY16E/17E EBITDA by 40%/42%, FY16E EPS/DPS by 59%/59%; our FY16E EBITDA/EPS imply 33%/48% downside from consensus forecast
- Dividends cut came earlier than expected. Opex uptrend despite weakening GGR. Maintain SELL with TP cut to HK\$2.90, 20% discount to 5-year historical avg. of 18x P/E and 13x EV/EBITDA

Freefall of EBITDA margin to 6.4% in 4Q15

Total revenue of HK\$11,149mn (-35% YoY, -2% QoQ) was in line with our expectation. Rolling chip volume fell 52% YoY and favorable win rate helped VIP GGR to decline at a slower pace at 47% YoY. Mass and slot GGR contracted 19% and 10% YoY. By properties, Grand Lisboa's GGR dropped the most, down 41% YoY with 3.2ppts EBITDA margin contraction. Satellite casinos continued to suffer ahead of suspension of Greek Mythology for renovation.

Other takeaways

1) 4Q15 was negatively impacted by HK\$143mn due to the shortfall in commission sharing with Greek Mythology and advance to promotors. 2) Mgmt maintains its guidance of >50% payout ratio. 3) Renovation of Greek Mythology to be completed by late FY16E might incur capex of HK\$1bn. 4) Lisboa Palace is targeted to be completed in 4Q17E.

One-off items adversely affected, but market is not merciful

Above mentioned one-off items are unlikely to be incurred in coming quarters. However, we believe market will still turn negative on the stock, on 1) lower-than-market expected 70% dividend payout ratio and 2) deterioration of Grand Lisboa is worrisome. SJM is currently trading at 38.9x FY16E P/E and 14.7x EV/EBITDA, which is not justifiable to us given its continued earnings contraction. We expect further drop in SJM's share price as we see 33%/48% downside from market's FY16E EBITDA/EPS estimates. Moreover, dividends are at risk.

Financials

HK\$ mn	FY13	FY14	FY15	FY16E	FY17E
Revenue	87,651	79,934	49,171	43,746	43,336
Net profit	7,706	6,731	2,465	815	(1,161)
Growth (%)	14.2%	-12.7%	-63.4%	-66.9%	-242.5%
EPS (HK\$)	1.39	1.20	0.44	0.14	(0.21)
DPS (HK\$)	1.00	0.84	0.25	0.05	-
P/E (x)	4.0x	4.7x	12.8x	38.9x	-27.3x
EV/EBITDA (x)	2.5x	3.0x	5.7x	14.7x	20.9x
Dividend yield (%)	17.9%	15.0%	4.5%	0.9%	0.0%
ROE (%)	32.9%	27.2%	10.6%	3.5%	-5.3%

Source: Company data, CMS (HK) estimates

Angela HAN LEE

+852 3189 6634

angelahanlee@cmschina.com.hk

Ryan YU

+852 3189 6268


ryanyu@cmschina.com.hk

WHAT'S NEW

Cut estimates and target price

SELL

Previous	SELL
Price	HK\$5.60
12-month Target Price (Potential up/downside)	HK\$2.90 (-48%)
Previous	HK\$3.70




Industry: Macau Gaming	
Hang Seng Index	19,415
HSCEI	8,171
Key Data	
52-week range (HK\$)	4.43 / 12.24
Market cap (US\$ mn)	4,087
Avg. daily volume (mn	11.0
BVPS (HK\$)	4.1
Shareholdings Structure	
STDM (54%)	3,062mn
Ms. Angela LEONG (9%)	488mn
No. of shares outstanding	5,657mn
Free float	37%

Related Research


- 1. Macau Gaming Encouraging CNY visitations; mass is the major beneficiary (NEUTRAL) 2016/02/15
- Macau Gaming January review: market-beating GGR on stabilization (NEUTRAL) 2016/02/01

Please see penultimate page for additional important disclosures. China Merchants Securities (CMS) is a foreign broker-dealer unregistered in the USA. CMS research is prepared by research analysts who are not registered in the USA. CMS research is distributed in the USA pursuant to Rule 15a-6 of the Securities Exchange Act of 1934 solely by Rosenblatt Securities, an SEC registered and FINRA-member broker-dealer.

Focus charts




Sources: Company data, CMS (HK) estimates




Sources: Company data, CMS (HK) estimates




Sources: Company data, Bloomberg, CMS (HK) estimates



Sources: Company data, CMS (HK) estimates



Sources: Company data, CMS (HK) estimates



Sources: Company data, Bloomberg, CMS (HK) estimates



Quarterly results

Quarterly results										
HK\$ mn	1Q14	2Q14	3Q14	4Q14	1Q15	2Q15	3Q15	4Q15	YoY	QoQ
Total Revenue	22,962	21,484	18,254	17,224	14,439	12,172	11,381	11,149	-35.3%	-2.0%
Gaming revenue	22,789	21,323	18,091	17,066	14,281	12,038	11,243	11,027	-35.4%	-1.9%
By segment										
 VIP gaming 	14,511	13,208	10,375	10,151	7,922	6,304	5,442	5,396	-46.8%	-0.8%
 Mass market gaming 	7,948	7,777	7,359	6,602	6,048	5,460	5,529	5,349	-19.0%	-3.3%
 Slot machines 	330	338	357	313	311	274	272	283	-9.7%	4.0%
By property										
 Casino Grand Lisboa 	8,280	7,928	6,878	6,501	5,198	3,963	3,540	3,835	-41.0%	8.3%
 Other self-promoted 	3,237	2,613	1,960	2,123	1,725	1,756	1,652	1,430	-32.6%	-13.4%
 Satellite casinos 	11,272	10,782	9,253	8,442	7,358	6,319	6,051	5,763	-31.7%	-4.8%
Non-gaming revenue	173	161	163	159	158	134	138	121	-23.6%	-12.2%
Adjusted EBITDA	2,190	2,254	1,751	1,568	1,241	1,021	884	716	-54.3%	-19.0%
- Casino Grand Lisboa	1,168	1,257	999	849	671	552	507	427	-49.7%	-15.8%
- Other self-promoted	445	439	310	267	251	219	144	135	-49.4%	-6.3%
- Satellite casinos	494	469	382	338	277	211	193	41	-87.9%	-78.8%
Adjusted EBITDA margin	9.5%	10.5%	9.6%	9.1%	8.6%	8.4%	7.8%	6.4%		
Net profit	1,878	2,024	1,528	1,301	1,004	787	285	389	-70.1%	36.5%
VIP gaming tables	582	568	564	574	530	492	458	428		
Mass market gaming tables	1,195	1,195	1,190	1,196	1,209	1,235	1,263	1,265		
Slot machines	2,971	2,813	2,806	2,834	2,793	2,711	2,737	2,603		
Rolling chip volume	537,200	466,495	360,000	355,860	247,200	195,508	160,000	170,737	-52.0%	6.7%
VIP win rate	2.70%	2.83%	2.88%	2.85%	3.18%	3.22%	3.36%	3.16%		
Occupancy rate (GL)	95.8%	94.8%	90.5%	91.7%	81.4%	78.8%	85.0%	86.8%		
Avg. room rate (GL) (HK\$)	2,385	2,303	2,261	2,351	2,509	2,289	1,743	1,579		

Source: Company data, CMS (HK) estimates



Earnings revision

Earnings rev	/ision									
HK\$ mn	Reported	Old	%	New	Old	%	New	Old	%	
11174 11111	FY15A	FY15E	chg	FY15E	FY15E	chg	FY16E	FY16E	chg	
Overall										
Total revenue	49,171	49,349	0%	43,746	43,922	0%	43,336	43,519	0%	
EBITDA	3,723	4,105	-9%	2,261	3,793	-40%	1,776	3,040	-42%	
EBITDA margin	8%	8%	-1ppt	5%	9%	-3ppts	4%	7%	-3ppts	
Net profit	2,465	3,135	-21%	815	1,975	-59%	(1,161)	(318)	n.a.	
EPS (HK\$)	0.44	0.56	-22%	0.14	0.35	-59%	(0.21)	(0.06)	n.a.	
DPS (HK\$)	0.25	0.39	-36%	0.05	0.12	-59%	-	-	-	Payout ratio at 35% vs. 50% guidance
Grand Lisboa										
Casino revenue	16,536	16,234	2%	14,977	13,557	10%	14,783	13,384	10%	
EBITDA	2,157	2,257	-4%	1,433	2,062	-30%	1,394	1,920		Cost hike at surprise
EBITDA margin	13%	14%	-1ppt	10%	15%	-6ppts	9%	14%	-5ppts	
VIP GGR	10,943	10,406	5%	9,540	7,813	22%	9,417	7,713	22%	
Mass GGR	5,593	5,828	-4%	5,437	5,744	-5%	5,367	5,671	-5%	Mass worse than expected
Other self-promot										
Casino revenue	6,563	6,770	-3%	5,964	6,450	-8%	5,887	6,368	-8%	
EBITDA	749	760	-1%	703	658	7%	685	579		Earnings stabilizing on "shift to mass"
EBITDA margin	11%	11%	0ppt	12%	10%	2ppts	12%	9%	3ppts	
\/ID 00D	0.470	0.400	000/	0.400	0.005	0.40/	0.000	0.700	0.40/	
VIP GGR	2,476	3,186	-22%	2,120	2,805	-24%	2,093	2,769	-24%	
Mass GGR	4,087	3,584	14%	3,844	3,645	5%	3,795	3,599	5%	
Satellite casinos	l.									
Casino revenue	25,491	25,821	-1%	22,383	23,542	-5%	21,767	22,903	-5%	
	·			·	•		-	·		No margin recovery after sharp fall in
EBITDA	722	940	-23%	193	964	-80%	27	454	-94%	4Q15
EBITDA margin	3%	4%	-1ppt	1%	4%	-3ppts	0%	2%	-2ppts	
VIP GGR	11,645	11,426	2%	9,540	9,415	1%	9,311	9,194	1%	
Mass GGR	13,846	14,395	-4%	12,843	14,127	-9%	12,456	13,709	-9%	
Lisboa Palace										
Net revenue	-	-	-	-	-	-	326	339	-	
EBITDA	-	-	-	-	-	-	(117)	(65)	-	
EBITDA margin	-	-	-	-	-	-	-36%	-19%	-	
VIP GGR	-	-	-	-	-	-	106	101	-	
Mass GGR		-	-	-	-	-	220	238	-	

Source: Company data, CMS (HK) estimates



Valuation

Our TP of HK\$2.90 is based on the average of 14x FY16E P/E and 10x EV/EBITDA, which are at a 20% discount to their five-year average of historical trading level, reflecting its continuous earnings decline until FY17E. Our TP implies FY16E/17E 20.1x/-14.1x P/E, and 8.4x/13.0x EV/EBITDA. Profitability deterioration of SJM is more severe than expected, and dividends payment is under risk given that the company is in need to finance its Lisboa Palace project from banks. We maintain SELL rating on SJM.

Risks: Potential re-rating catalysts are 1) effective market share protection from Cotai players and 2) reverse of margin declining trend with effective cost control. Downside risks to our forecasts are: 1) worse-than-expected cost control strategy, and 2) potential cut in dividend payout ratio.

Peer valuation table

		Rating	Target Px	Current Px (Icl crncy)	+/-	Mkt Cap	52-Wk Price	Avg T/O		P/E (x)	
Company Tie	Ticker				side	(US\$ mn)	(Icl crncy)	(US\$mn)	FY14	FY15E	FY16E
Galaxy	27 HK	BUY	29.60	26.40	12%	14,514	19.02 / 43.01	48.5	10.8	22.7	18.6
SJM	880 HK	SELL	2.90	5.60	-48%	4,087	4.43 / 12.24	7.4	4.7	12.8	38.9
Wynn Macau	1128 HK	NEUTRAL	8.90	8.88	0%	5,953	6.84 / 22.70	15.1	7.1	19.2	23.2
Sands China	1928 HK	BUY	28.20	27.05	4%	28,164	20.75 / 39.85	56.3	11.0	19.2	19.8
MGM China	2282 HK	SELL	8.00	8.91	-10%	4,369	7.83 / 18.74	7.9	5.9	10.9	16.6
Melco Crown	MPEL US	BUY	20.80	16.32	27%	8,887	12.05 / 27.39	49.0	14.7	83.2	47.0
Simple Avg									9.1	28.0	27.3
Mkt Cap Avg									10.4	27.6	24.5

Compony Ti	Ticker	EV/	EV/EBITDA (x)			ROE (%)		Divide	Dividends Yield (%)			Net Debt/Equity (%)		
Company Ti		FY14	FY15E	FY16E	FY14	FY15E	FY16E	FY14	FY15E	FY16E	FY14	FY15E	FY16E	
Galaxy 27	7 HK	7.8	13.1	11.0	27.4	12.3	13.7	2.8	2.1	1.9	(24.8)	(7.9)	(19.5)	
SJM 88	80 HK	3.0	5.7	14.7	27.2	10.6	3.5	15.0	4.5	0.9	(34.5)	(41.4)	15.6	
Wynn Macau 11	128 HK	6.4	14.1	12.9	91.5	60.1	41.1	19.7	2.5	2.2	110.9	493.7	403.1	
Sands China 19	928 HK	9.0	14.1	14.9	39.6	25.2	27.5	7.4	7.4	7.4	10.3	35.8	66.6	
MGM China 22	282 HK	5.1	9.4	12.1	90.0	63.3	32.6	15.1	2.8	1.8	(1.8)	128.4	169.0	
Melco Crown M	IPEL US	10.3	14.4	11.0	14.2	2.4	4.5	2.0	4.3	0.6	53.8	54.2	59.5	
Simple Avg		6.9	11.8	12.8	48.3	29.0	20.5	10.3	3.9	2.5				
Mkt Cap Avg		8.0	13.1	13.2	40.8	24.1	21.4	7.7	4.9	4.0				

Source: Company data, Bloomberg, CMS (HK) estimates



Financial Summary

Statement of financial	positi	on			
HK\$ mn	2013	2014	2015	2016E	2017E
Current Assets	27,826	26,128	18,677	17,216	17,315
Cash and cash equivalents	11,145	9,547	10,372	9,111	9,207
Account receivables	1,510	2,094	1,658	1,475	1,461
Other receivables	-	-	-	-	-
Inventories	62	63	63	46	62
Other current assets	15,109	14,424	6,584	6,584	6,584
Non-current assets	14,543	16,087	18,178	30,593	34,396
Property and Equipment	8,325	11,431	14,054	26,621	30,561
Land use rights	2,771	2,729	2,635	2,490	2,353
Intangible assets	21	14	8	2	2
Other non-current assets	3,426	1,913	1,481	1,481	1,481
Total assets	42,369	42,215	36,855	47,809	51,711
Current liabilities	16,022	15,033	11,297	10,441	10,660
ST borrowings	318	258	158	158	158
Account payables	15,319	14,383	10,730	9,874	10,093
Other current liabilities	385	391	409	409	409
Non-current liabilities	2,891	2,320	2,078	14,078	19,078
LT borrowings	1,191	733	554	12,554	17,554
Other non-current liabilities	1,700	1,587	1,524	1,524	1,524
Total liabilities	18,913	17,353	13,375	24,519	29,738
Common stock - par value	5,554	11,232	11,236	11,236	11,236
Reserves	17,850	13,532	12,090	11,914	10,610
Minority interest	52	98	154	140	126
Shareholders' equity	23,455	24,862	23,479	23,290	21,972
Total equity and liabilities	42,369	42,215	36,855	47,809	51,711

Statement of cash flow	NS				
HK\$ mn	2013	2014	2015E	2016E	2017E
CF from OA	9,560	6,252	4,515	1,426	1,599
Net income	7,706	6,731	2,465	815	(1,161)
D&A	1,185	1,142	1,143	1,557	2,799
Finance costs	90	73	52	37	666
Changes of WC	982	(1,691)	(3,217)	(656)	217
Others	(403)	(3)	4,072	(327)	(922)
CF from IA	(4,431)	(2,621)	(1,783)	(13,696)	(6,359)
Capital expenditure	(3,440)	(4,260)	(3,750)	(14,000)	(6,655)
Investment income	305	372	254	276	242
Other investments	(1,296)	1,268	1,713	28	53
CF from FA	(5,916)	(5,230)	(1,908)	11,009	4,857
Borrowings	(235)	(517)	(278)	12,000	5,000
Share capital and reserves	46	1,267	-	-	-
Dividends	(5,551)	(5,769)	(4,073)	(991)	(143)
Others	(176)	(212)	2,443	-	-
Forex adjustment	-	-	-	-	-
Net cash flow	(786)	(1,599)	825	(1,261)	96

Source: Company	data,	CMS	(HK)	estimates
-----------------	-------	-----	------	-----------

Income statem	ent				
HK\$ mn	2013	2014	2015	2016E	2017E
Total net revenue	87,651	79,934	49,171	43,746	43,336
Gaming tax	(33,425)	(30,496)	(18,820)	(16,815)	(16,647)
Marketing expenses	(38,459)	(33,789)	(18,455)	(16,455)	(17,098)
Inventory consumed	(293)	(266)	(249)	(181)	(245)
Other OP expenses	(7,927)	(8,846)	(9,431)	(9,799)	(10,181)
Adj. EBITDA	8,676	7,763	3,862	2,404	1,926
Op Profit	7,548	6,537	2,216	497	(834)
Fin. costs	(90)	(73)	(52)	(37)	(666)
Inv income	305	372	254	276	242
Other non-OP items	12	33	72	72	73
Pre-tax Profit	7,775	6,870	2,490	808	(1,184)
Taxes	(53)	(88)	(38)	(6)	9
After-tax Profit	7,723	6,781	2,452	801	(1,175)
NCI	(16)	(51)	13	13	14
Net Profit	7,706	6,731	2,465	815	(1,161)
EPS (HK\$)	1.39	1.20	0.44	0.14	(0.21)
DPS (HK\$)	1.00	0.84	0.25	0.05	-

_					
Financial ratios					
	2013	2014	2015	2016E	2017E
YoY growth rate					
Total revenue	10.2%	-8.8%	-38.5%	-11.0%	-0.9%
Adj. EBITDA	13.7%	-10.5%	-50.3%	-37.8%	-19.9%
Op profit	14.4%	-13.4%	-66.1%	-77.6%	-267.9%
Net profit	14.2%	-12.7%	-63.4%	-66.9%	-242.5%
Profitability					
EBITDA margin	9.9%	9.7%	7.9%	5.5%	4.4%
OP margin	8.6%	8.2%	4.5%	1.1%	-1.9%
NP margin	8.8%	8.4%	5.0%	1.9%	-2.7%
ROE	32.9%	27.2%	10.6%	3.5%	-5.3%
ROIC	25.3%	21.2%	9.6%	2.2%	-1.2%
Liquidity					
Debt / equity	6.5%	4.0%	3.1%	54.9%	81.1%
Net debt / equity	-41.2%	-34.5%	-41.4%	15.6%	38.9%
Current ratio	1.7x	1.7x	1.7x	1.6x	1.6x
Quick ratio	0.8x	0.8x	1.1x	1.0x	1.0x
Operating efficiency					
Asset turnover	2.1x	1.9x	1.3x	0.9x	0.8x
Valuation ratios					
P/E	4.0x	4.7x	12.8x	38.9x	-27.3x
P/B	1.3x	1.3x	1.4x	1.4x	1.5x
EV/EBITDA	2.5x	3.0x	5.7x	14.7x	20.9x
Dividend yield	17.9%	15.0%	4.5%	0.9%	0.0%
		_		•	_



Investment Ratings

Industry Rating	Definition
OVERWEIGHT	Expect sector to outperform the market over the next 12 months
NEUTRAL	Expect sector to perform in-line with the market over the next 12 months
UNDERWEIGHT	Expect sector to underperform the market over the next 12 months
Company Rating	Definition
BUY	Expect stock to generate 10%+ return over the next 12 months

Analyst Disclosure

NEUTRAL

SELL

The analysts primarily responsible for the preparation of all or part of the research report contained herein hereby certify that: (i) the views expressed in this research report accurately reflect the personal views of each such analyst about the subject securities and issuers; and (ii) no part of the analyst's compensation was, is, or will be directly or indirectly, related to the specific recommendations or views expressed in this research report.

Expect stock to generate +10% to -10% over the next 12 months

Expect stock to generate loss of 10%+ over the next 12 months

Regulatory Disclosure

Please refer to the important disclosures on our website http://www.newone.com.hk/cmshk/en/disclosure.html.

Disclaimer

This document is prepared by China Merchants Securities (HK) Co., Limited ("CMS HK"). CMS HK is a licensed corporation to carry on Type 1 (dealing in securities), Type 2 (dealing in futures), Type 4 (advising on securities), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities under the Securities and Futures Ordinance (Chapter 571). This document is for information purpose only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer or solicitation of an offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever to buy or sell any security, financial instrument or any investment or other specific product. The securities, instruments or strategies discussed in this document may not be suitable for all investors, and certain investors may not be eligible to participate in some or all of them. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. CMS HK is not registered as a broker-dealer in the United States and its products and services are not available to U.S. persons except as permitted under SEC Rule 15a-6.

The information and opinions, and associated estimates and forecasts, contained herein have been obtained from or are based on sources believed to be reliable. CMS HK, its holding or affiliated companies, or any of its or their directors, officers or employees ("CMS Group") do not represent or warrant, expressly or impliedly, that it is accurate, correct or complete and it should not be relied upon. CMS Group will not accept any responsibility or liability whatsoever for any use of or reliance upon this document or any of the content thereof. The contents and information in their document are only current as of the date of their publication and will be subject to change without prior notice. Past performance is not indicative of future performance. Estimates of future performance are based on assumptions that may not be realized. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. Opinions expressed herein may differ or be contrary to those expressed by other business divisions or other members of CMS Group as a result of using different assumptions and/or

This document has been prepared without regard to the individual financial circumstances and investment objectives of the persons who receive it. Use of any information herein shall be at the sole discretion and risk of the user. Investors are advised to independently evaluate particular investments and strategies, take financial and/or tax advice as to the implications (including tax) of investing in any of the securities or products mentioned in this document, and make their own investment decisions without relying on this publication.

CMS Group may have a long or short position, make markets, act as principal or agent, or engage in transactions in securities of companies referred to in this document and may also perform or seek to perform investment banking services or provide advisory or other services for those companies. This document is for the use of intended recipients only and this document may not be reproduced, distributed or published in whole or in part for any purpose without the prior consent of CMS Group. CMS Group will not be liable for any claims or lawsuits from any third parties arising from the use or distribution of this document. This document is for distribution only under such circumstances as may be permitted by applicable law. This document is not directed at you if CMS Group is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. In particular, this document is only made available to certain US persons to whom CMS Group is permitted to make available according to US securities laws, but cannot otherwise be made available, distributed or transmitted, whether directly or indirectly, into Japan and Canada and not to the general public in the People's Republic of China (for the purpose of this document, excluding Hong Kong, Macau and Taiwan).



Important Disclosures for U.S. Persons

This research report was prepared by CMS HK, a company authorized to engage in securities activities in Hong Kong. CMS HK is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution solely to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Rosenblatt Securities Inc, 20 Broad Street 26th Floor, New York NY 10005, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through CMS HK. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set out below.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Rosenblatt Securities Inc. or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Rosenblatt Securities Inc, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Rosenblatt Securities Inc. is not aware of any material conflict of interest as of the date of this publication.

Compensation and Investment Banking Activities

Rosenblatt Securities Inc. or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither CMS HK nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

CMS HK may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of CMS HK.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by CMS HK with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of CMS HK and CMS HK accepts no liability whatsoever for the actions of third parties in this respect.

Hong Kong

China Merchants Securities (HK) Co., Ltd.

Address: 48/F, One Exchange Square, Central, Hong Kong

Tel: +852 3189 6888 Fax: +852 3101 0828